So what does that have to do with the shareholders of BioAmber? Even if LCY does return to the public and start to trade again in a few years it has nothing to do with BioAmber shareholders.
The shareholders of BioAmber will not have any shares in LCY unless they would purchase them on the open market. BioAmber shareholders will not just magically have shares in LCY when it goes public again. LCY’s lawyer made it abundantly clear that they would not be paying shareholders anything and by all right they do not need to. LCY and or Visolis owe nothing to BioAmber shareholders at all.
Visolis/LCY paid their purchase amount of $4.3 mil when the liquidation closed and they received the plant, IP, trademarks, trade names, patents, R&D breakthroughs and everything else of value. It’s all right in the No longer sealed 6th monitors report along with the LOI and winning bid of Visolis/LCY.
They don’t owe BioAmber shareholders anything at all he’ll for that matter nobody does